China’s first new crown mRNA vaccine approved for clinical trial

Novel coronavirus mRNA vaccine candidate (ARCoV), China’s military network Beijing, June 24, special correspondent Zhuang Yingna and reporter Shao Longfei reported: the joint development of the Military Medical Research Institute of the Academy of military science and local enterprises has approved the approval of the National Drug Administration and clinical trial in June 19th. This is the first new crown mRNA vaccine approved for clinical trials in China.

Since the outbreak of novel coronavirus pneumonia, the Academy of Military Medical Sciences of the Academy of Military Sciences has been deploying emergency research and research projects, and has promoted the development of new crown vaccines for several technical routes. The new crown mRNA vaccine made in China is another high-tech vaccine which has been successfully developed and approved by the hospital after the recombinant new crown vaccine (adenovirus vector). The results showed that the new coronal mRNA vaccine could not only induce high level neutralizing antibody in mice and cynomolgus monkeys, but also induce protective T cell immune response. The experimental results of cynomolgus monkeys showed that the vaccinated animals could tolerate the attack of high titer new coronavirus, effectively prevent virus replication and lung pathological progress, and show good protective effect.

MRNA vaccine is a new vaccine form in recent years. Its basic principle is to introduce the target mRNA of antigen expression into the body through a specific delivery system, express the protein in the body and stimulate the body to produce specific immune response, so that the body can obtain immune protection. There is a high technical threshold in the research and development of mRNA vaccine. At present, only a few kinds of mRNA vaccine developed in the United States and Germany have entered the clinical research stage. China has never approved the introduction of mRNA vaccine into clinical research before.

Qin Chengfeng, the project leader and researcher of the Academy of military medicine of the Academy of Military Sciences, said that the domestic new crown mRNA vaccine has three advantages: first, the selection of vaccine antigen target is more accurate, the specificity of neutralizing antibody produced by induction is high, and the safety of vaccine is better; second, the core raw materials and equipment have all been localized, which can realize the rapid expansion of production capacity; third, the use of single precharge needle The dosage form can be stored at room temperature for one week or at 4 ℃ for a long time. The cost of cold chain is low and it is easy to realize mass vaccination.

It is reported that the new crown mRNA vaccine has been produced in multiple batches according to the requirements of clinical trials, and phase I clinical trials will be officially launched in Shulan (Hangzhou) hospital.